APA

Martín I., Navarro B., Serrano A., Villamón E., Calabuig M., Solano C., Chaves F. J., Yagüe N., Orts M., Amat P., Fuentes A., Seda E., García F., Hernández-Boluda J. C. & Tormo M. (20200317). Impact of clinical features, cytogenetics, genetic mutations, and methylation dynamics of CDKN2B and DLC-1 promoters on treatment response to azacitidine. : Annals of hematology.

Chicago

Martín Iván, Navarro Blanca, Serrano Alicia, Villamón Eva, Calabuig Marisa, Solano Carlos, Chaves Felipe Javier, Yagüe Nuria, Orts Maribel, Amat Paula, Fuentes Azahara, Seda Enrique, García Francisca, Hernández-Boluda Juan Carlos and Tormo Mar. 20200317. Impact of clinical features, cytogenetics, genetic mutations, and methylation dynamics of CDKN2B and DLC-1 promoters on treatment response to azacitidine. : Annals of hematology.

Harvard

Martín I., Navarro B., Serrano A., Villamón E., Calabuig M., Solano C., Chaves F. J., Yagüe N., Orts M., Amat P., Fuentes A., Seda E., García F., Hernández-Boluda J. C. and Tormo M. (20200317). Impact of clinical features, cytogenetics, genetic mutations, and methylation dynamics of CDKN2B and DLC-1 promoters on treatment response to azacitidine. : Annals of hematology.

MLA

Martín Iván, Navarro Blanca, Serrano Alicia, Villamón Eva, Calabuig Marisa, Solano Carlos, Chaves Felipe Javier, Yagüe Nuria, Orts Maribel, Amat Paula, Fuentes Azahara, Seda Enrique, García Francisca, Hernández-Boluda Juan Carlos and Tormo Mar. Impact of clinical features, cytogenetics, genetic mutations, and methylation dynamics of CDKN2B and DLC-1 promoters on treatment response to azacitidine. : Annals of hematology. 20200317.